LLY
Lilly (Eli)
$1,107.08
▲ 0.5%Updated Today 5:06 AM ET
▲ Up 39.9% over the last 12 months
Market Cap
$1.04T
P/E
41.46x
Forward P/E (est.)
29.61x
ROE
101.3%
Revenue Growth
47.4%
EPS Growth
128.8%
Profit Margin
35.0%
FCF Yield
0.6%
Debt / Equity
1.6x
ROIC
—
Interest Coverage
—
Current Ratio
1.5x
Dividend Yield
0.6%
Implied Growth (rev. DCF)
—
Rating Score
69/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what LLY's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. LLY trades near $1,107.08, above its 50-day average ($1,017.38) and 200-day average ($969.73). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 61 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. LLY's is $37.30 (~3.4% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month LLY found buyers near $1,052.15 (support) and sellers near $1,182.73 (resistance); its 52-week range is $623.78–$1,182.73. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.0× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Lilly (Eli) (LLY) is a mega-cap company in the Pharmaceuticals industry, part of the Health Care sector of the S&P 500, with a market value around $1.04T.
In its latest reported year it generated about $65.18B in revenue and $20.64B in net profit.
Our model rates LLY Favorable (69/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
23.2%
Revenue moved from $28.32B in 2021 to $65.18B in 2025, a 23.2% compound annual growth rate. The most recent year grew a strong 47.4% year over year. Consistent top-line growth is one sign of healthy demand.
Gross Margin
82.8%
Operating Margin
43.6%
Net Margin
31.7%
ROE
101.3%
Lilly (Eli) keeps about 35.0% of each sales dollar as net profit, with a 82.8% gross margin and 43.6% operating margin. Return on equity is 101.3%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$29.47B
Net Debt
$24.19B
Net Debt / EBITDA
—
Debt / Equity
1.6x
Leverage: debt-to-equity is 1.6x, with a current ratio of 1.5x. That is elevated leverage, which raises risk if earnings or rates move against it. It carries roughly $29.47B of total debt against $5.28B of cash.
Operating CF
$16.81B
Free Cash Flow
$16.81B
FCF Margin
25.8%
In the latest year Lilly (Eli) produced about $16.81B of operating cash flow and $16.81B of free cash flow after capital spending. That is a free-cash-flow yield of about 0.6% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
41.46x
P/S
16.3x
P/B
37.76x
EV / EBITDA
—
LLY trades at 41.5x trailing earnings (about 29.6x on estimated forward earnings), 16.3x sales, and 37.8x book value. That is a rich multiple that prices in a lot of future growth.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How LLY stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), LLY ranks #7 of 59 by our overall rating. It trades at a premium versus the sector on earnings (41.5x P/E vs. 25.5x median) with a higher return on equity (101.3% vs. 14.9%) and faster revenue growth (47.4% vs. 7.9%).
P/E vs sector
41.5x
median 25.5x
ROE vs sector
101.3%
median 14.9%
Growth vs sector
47.4%
median 7.9%
Sector rank
#7
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$3,549.00 – $5,820.36
vs. $1,107.08 today · expected CAGR 26% – 39%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $94.51B | $137.04B | $198.71B | $288.12B | $417.78B |
| Net income | $30.24B | $43.85B | $63.59B | $92.20B | $133.69B |
| EPS | $32.11 | $46.57 | $67.52 | $97.90 | $141.96 |
| Share price (low) | $802.85 | $1,164.13 | $1,687.99 | $2,447.59 | $3,549.00 |
| Share price (high) | $1,316.67 | $1,909.18 | $2,768.30 | $4,014.04 | $5,820.36 |
| CAGR (low–high) | -27% / 19% | 3% / 31% | 15% / 36% | 22% / 38% | 26% / 39% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for LLY:
- Revenue is growing 47.4% a year, a sign of real demand.
- High net margins (35.0%) point to pricing power or efficiency.
- Strong return on equity (101.3%) shows capital is put to work well.
- Our model's overall read is Favorable (69/100).
The case against LLY:
- Elevated leverage (debt/equity 1.6x) adds financial risk.
- A rich 41.5x earnings multiple prices in a lot of growth.
- Limited free cash flow at today's price.
Valuation risk — at 41.5x earnings, disappointing results could compress the multiple.
Balance-sheet risk — debt/equity of 1.6x magnifies the impact of higher rates or weaker earnings.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Lilly (Eli) is a mega-cap health care business still growing nicely, with solid profitability, and a heavier debt load to watch. It trades at 41.5x earnings, which our model scores Favorable (69/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
LLY — frequently asked questions
Is LLY a good stock to buy?
We don't give buy or sell advice. Our model rates Lilly (Eli) Favorable (69/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is LLY's rating on The Stocks School?
Lilly (Eli) currently scores 69/100 (Favorable) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does LLY's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Lilly (Eli)'s SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for LLY calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this LLY analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell LLY. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.